NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, Sébastien Carrère, Anne Ducassou, Marie‐Pierre Sunyach, Péter Ágoston, Angela Hong, A. Mervoyer, Marco Rastrelli,

The Lancet Oncology · 2019 · 503 citations · 32 references

DOIFull text

Open access

Concepts

References

32